bluuebunny/crossref_metadata_2025_split huggingface dataset:
Over‐expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis
Authors: Ohuchida K , Mizumoto K , Miyasaka Y , Yu J , Cui L , Yamaguchi H , Toma H , Takahata S , Sato N , Nagai E , Yamaguchi K , Tsuneyoshi M , Tanaka M 
Published: October 2007

AbstractControversy exists regarding the clinical significance of S100A2 in the progression of tumours. In pancreatic cancer, little is known about the role of S100A2. The aim of this study was to clarify the clinical significance of S100A2 expression in pancreatic carcinogenesis. We microdissected invasive ductal carcinoma (IDC) cells from 22 lesions, pancreatic intraepithelial neoplasia (PanIN) cells from five lesions, intraductal papillary mucinous neoplasm (IPMN) cells from 38 lesions, pancreatitis‐affected epithelial (PAE) cells from 16 lesions, and normal ductal cells from 18 normal pancreatic tissues. S100A2 expression in 14 pancreatic cancer cell lines, microdissected cells and formalin‐fixed paraffin‐embedded (FFPE) samples was examined by quantitative reverse transcription‐polymerase chain reaction (qRT–PCR). Microdissection analyses revealed that IDC cells expressed higher levels of S100A2 than did IPMN, PAE or normal cells (all comparisons, p < 0.007). Cell lines from metastatic sites expressed higher levels of S100A2 than those from primary sites. PanIN cells expressed higher levels of S100A2 than normal cells (p = 0.018). IDC cells associated with poorly differentiated adenocarcinoma expressed higher levels of S100A2 than did IDC cells without poorly differentiated adenocarcinoma (p = 0.006). Analyses of FFPE samples revealed that levels of S100A2 were higher in samples from patients who survived < 1000 days after surgery than in those from patients who survived > 1000 days (p = 0.043). Immunohistochemical analysis was consistent with qRT–PCR. S100A2 may be a marker of tumour progression or prognosis in pancreatic carcinogenesis and pancreatic cancer. Copyright © 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Phase 1 trial of O6‐benzylguanine and BCNU in children with CNS tumors: A Children's Oncology Group study
Authors: Adams Denise M. , Zhou Tianni , Berg Stacey L. , Bernstein Mark , Neville Kathleen , Blaney Susan M. 
Published: October 2007

AbstractBackgroundEfficacy of nitrosoureas is limited by host repair of drug‐induced alkylation. O6‐benzylguanine (O6‐BG), an inhibitor of host alkylation repair, and BCNU were studied in children with refractory/untreatable central nervous system tumors to determine dose‐limiting toxicities (DLTs) and maximum tolerated dose (MTD) of BCNU administered following O6‐BG.ProcedureO6‐BG (120 mg/m2 IV over 1 hr) was followed by BCNU (IV over 1 hr). Cohorts of three to six patients were treated with escalating doses of BCNU. Courses were repeated every 6 weeks. Patients in Stage 1 were accrued irrespective of prior treatment. Once the MTD was exceeded, Stage II accrual was limited to less heavily pretreated patients (≤ two prior chemotherapy regimens, no prior central axis radiation, no prior bone marrow transplant, and no bone marrow involvement).ResultsTwelve patients in Stage I and 13 in Stage II (less heavily pretreated patients only) were evaluable for toxicity. The MTD of BCNU administered with O6‐BG (120 mg/m2 IV) was 58 mg/m2 in less‐heavily pretreated patients. Myelosuppression, which was cumulative in some patients receiving multiple cycles of therapy, was the predominate DLT. Twenty‐four patients were evaluable for response: after two courses of therapy, 6 had stable disease, 17 had progressive disease, and 1 patient had a minor response but progressed after four courses of therapy.ConclusionsBased on lack of activity of this combination in adult phase II studies, no further testing of O6‐BG plus BCNU in children is planned. Strategies to decrease hematopoeitic toxicity of BCNU plus O6‐BG are required. Pediatr Blood Cancer 2008;50:549–553. © 2007 Wiley‐Liss, Inc.
Correction of chronic granulomatous disease after second unrelated‐donor umbilical cord blood transplantation
Authors: Parikh Suhag H. , Szabolcs Paul , Prasad Vinod K. , Lakshminarayanan Sonali , Martin Paul L. , Driscoll Timothy A. , Kurtzberg Joanne 
Published: October 2007

AbstractAllogeneic hematopoietic stem cell transplantation (HSCT) is curative for chronic granulomatous disease (CGD), but many patients lack a suitably matched related donor. We report successful outcomes after mismatched, unrelated‐donor umbilical cord blood transplantation (uUCBT) in two boys with X‐linked CGD. Both patients experienced autologous recovery after first transplants, required second transplants to achieve durable donor engraftment, and are alive 27 and 15 months post‐transplant. Both had invasive fungal disease and received granulocyte transfusions. In conclusion, uUCBT is effective in children with CGD, but immunosuppression in the conditioning regimen may need to be increased to decrease the risk of graft rejection. Pediatr Blood Cancer © 2007 Wiley‐Liss, Inc.
Outcome of children with aplastic anemia treated with immunosuppressive therapy
Authors: Pongtanakul Bunchoo , Das Prabodh Kumar , Charpentier Karen , Dror Yigal 
Published: October 2007

AbstractBackgroundImmunosuppressive therapy (IST) is the alternative treatment in children with aplastic anemia (AA) who do not have an HLA‐matched sibling. The aim of this study is to evaluate the outcome of children with AA treated with IST.MethodsWe retrospectively reviewed the hospital records of children with AA from 1984 to 2004, treated at our institution with antithymocyte globulin (ATG), cyclosporine (CS), and short course of prednisone.ResultForty‐two patients were treated with IST (24 boys, 18 girls); of whom 26% received G‐CSF. The median age at diagnosis was 8.5 years. Sixty‐nine, 19, and 12% were diagnosed with severe, very severe, and moderate AA, respectively. Twenty‐one percent had hepatitis‐associated AA. Median follow‐up time was 53.3 months. Sixty‐two percent had complete response; 19% had partial response. Two patients relapsed and received a second course of ATG; both had a partial response. The actuarial 5 years survival rate was 67.5%. Two patients developed myelodysplastic syndrome (MDS); both received long‐term G‐CSF and had partial response after two courses of IST. Fifteen percent of survivors had significant hypertension which persisted after CS was discontinued.ConclusionsThis study shows promising response in children with AA treated with IST; however, the outcome was inferior to our institutional results with hematopoietic stem cell transplantation from a sibling donor. Hypertension and MDS are late complications. Longer follow‐up, larger cohorts, and prospective studies are warranted to evaluate late complications and risk factors. Pediatr Blood Cancer 2008;50:52–57. © 2007 Wiley‐Liss, Inc.
Feasibility of metronomic maintenance chemotherapy following high‐dose chemotherapy for malignant central nervous system tumors
Authors: Choi L. Mi Rim , Rood Brian , Kamani Naynesh , La Fond Deborah , Packer Roger J. , Santi Maria Rita , MacDonald Tobey J. 
Published: October 2007

AbstractBackgroundChildren less than 5 years of age with malignant central nervous system (CNS) tumors, continue to have a high rate of morbidity and mortality following administration of conventional therapy. In an attempt to avoid the neurologic sequelae associated with craniospinal radiation, strategies such as high‐dose chemotherapy (HDCT) followed by peripheral stem cell rescue have been used successfully. Metronomic chemotherapy has also been reported as a potential new treatment strategy in solid tumors, particularly in adults.ProcedureA retrospective chart analysis was performed on 10 patients less than 5 years of age with CNS tumors treated with metronomic chemotherapy shortly after HDCT as part of their clinical care.ResultsMetronomic chemotherapy was associated with minimal toxicity and all patients maintained a good quality of life. At the time of this report, all 10 patients are alive. Two patients have relapsed, and the remaining eight, including six patients with metastatic disease, continue to have stable clinical and radiographic disease at a mean of 20 months from the time of diagnosis.ConclusionsMetronomic chemotherapy in this patient population is feasible and shows encouraging preliminary results, especially in patients with metastatic disease who have not received craniospinal radiation. Further investigation of this strategy in newly diagnosed patients with CNS tumors is warranted. Pediatr Blood Cancer 2008;50:970–975. © 2007 Wiley‐Liss, Inc.
Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET
Authors: Saran Frank , Baumert Brigitta G. , Creak Antonia L. , Warrington Alan P. , Ashley Sue , Traish Daphne , Brada Michael 
Published: October 2007

AbstractPurposeTo evaluate the efficacy and toxicity of hypofractionated stereotactic radiotherapy in the management of locally recurrent or residual central nervous system (CNS) primitive neuroectodermal tumors (PNETs).Patients and MethodsBetween 1991 and 2005, 12 patients with locally recurrent medulloblastoma and two patients with residual supratentorial PNET were treated with hypofractionated stereotactic conformal radiotherapy (SCRT). Nine patients were treated for first recurrence, two patients after the 2nd, and one patient after 3rd recurrence. Median age at diagnosis was 20 years (range: 4–35 years) and median age at SCRT 25 years (range: 7–41 years). Nine of 12 patients underwent resection at recurrence and 13 patients received at least one cycle of chemotherapy prior to SCRT. All received focal SCRT (30–40 Gy/6–8 #) using non‐coplanar arcs (n = 6) or fixed conformal non‐coplanar fields (n = 8).ResultsMedian overall survival was 29 months (95% CI: 6–51 months) and median progression‐free survival was 12 months (95% CI: 5–19 months). Local progression‐free survival at 1 and 3 years was 80% (95% CI: 55–100%) and 48% (95% CI: 11–85%). Causes of death were recurrent CNS disease (n = 7), herpes encephalitis (n = 1), and metastatic PNET outside the CNS (n = 1).ConclusionHypofractionated SCRT provides effective local control with acceptable toxicity for patients with recurrent localized PNET. However, overall long‐term disease control is rare and limited by the occurrence of CSF mediated relapses, which thus could benefit from intensive systemic chemotherapy as part of the primary relapse strategy even in local recurrences. Larger multi‐national studies will be necessary to assess the value of such combined treatment approaches. Pediatr Blood Cancer 2008;50:554–560. © 2007 Wiley‐Liss, Inc.
Prescribing of sulfasalazine, azathioprine and methotrexate round pregnancy—a descriptive study
Authors: Vroom Fokaline , van Roon Eric N. , van den Berg Paul B. , Brouwers Jacobus R.B.J. , de Jong‐van den Berg Lolkje T.W. 
Published: October 2007

AbstractPurposeContinuation or discontinuation of drugs during pregnancy in chronic diseases is an issue of concern. Information on prescribing of disease modifying anti‐rheumatic drugs (DMARDs) during pregnancy is scarce. In this study, we report prescribing patterns round pregnancy of sulfasalazine (SSZ), azathioprine (AZA), methotrexate (MTX) and co‐medications among women to whom one of these DMARDs were prescribed before pregnancy.MethodsThe pregnancy‐interaction database (IADB.nl, 1994–2004), containing pharmacy dispensing data from Northern‐ Netherlands, was used. Women to whom SSZ (N = 13), AZA (N = 10) or MTX (N = 6) was prescribed before their first pregnancy were identified and described in detail.ResultsAZA and SSZ are continued during pregnancy by 60% and 38% of the women, respectively, MTX was stopped before pregnancy. Among women receiving SSZ (N = 13) as their initial DMARD, anti‐inflammatory and anti‐rheumatic drugs (69%) and analgesics (45%) were the most commonly prescribed co‐medications. Among women receiving AZA (N = 8) as their initial DMARD, corticosteroids for systemic use (100%) and intestinal anti‐inflammatory agents (88%) were the most commonly prescribed co‐medications. All women receiving intestinal anti‐inflammatory drugs before pregnancy continued this during pregnancy, in contrast to other co‐medications which were mainly discontinued.ConclusionsOur study showed that DMARDs and co‐medication are received before, during and after pregnancy, although no specific prescription patterns were found. Administrative databases, such as the pregnancy‐IADB.nl, are useful in describing drug‐prescribing patterns for better understanding of drug prescribing around pregnancy in daily practice. Based on these data, we conclude that prescribing of DMARDs and related co‐medication is based on the individual patient. Copyright © 2007 John Wiley & Sons, Ltd.
Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays
Authors: Winters Mary , Dabir Bhavana , Yu Minshu , Kohn Elise C. 
Published: October 2007

AbstractApplication of novel technology to clinical samples requires optimization of procedures. Reverse phase protein lysate arrays use femtomolar quantities of tissue lysate from clinical samples with which to profile biochemical events happening in the tumor. We analyzed the effects of different tissue solubilization buffers on frozen ovarian tumor samples in order to identify the system with the best signal intensity dynamic range, reproducibility, tissue solubility, and signal consistency. A modified RIPA‐like buffer supplemented with DTT and SDS was deemed optimal.
Titanium and zirconium complexes containing modified TREN ligands for the polymerization of 1‐alkenes—A comparative study
Authors: Sudhakar Padmanabhan 
Published: October 2007

AbstractThe titanium and zirconium complexes in C3 and Cs symmetric forms synthesized from corresponding aminotriols in combination with MAO polymerized 1‐hexene in a controlled manner. When the polymerization temperature was lowered, they gave high molecular weight monodisperse polyhexene with narrow polydispersities indicating quazi‐living systems. The isotactic polyhexene obtained from C3 titanium catalyst has the molecular weight of around 46,500 with PDI of 1.3 and the hemi‐isotactic polymer from Cs titanium catalyst has the molecular weight of around 617,000 with PDI of 1.3. The analogues zirconium complexes upon activation with MAO polymerize hexene to give polyhexene having molecular weight of 53,000 (C3) and 626,000 (pseudo‐Cs) with PDI ranging from 1.2 to 1.4. The MIX‐titanium catalyst prepared from the 50:50 mixture of aminotriols was also able to polymerize 1‐hexene and the GPC traces of the polyhexene suggests that even though the catalyst was formed from the mixture of aminotriols, the C3 and Cs symmetry of the catalysts retain its originality avoiding the formation of aggregates or polymeric forms. When one of the arms of aminotriol was methylated yield C2 and meso aminodiol ligands and their corresponding titanium and zirconium complexes gave higher molecular weight polyhexenes with lower PDI (C2‐Zr‐Mn: 260,000; PDI: 1.05–1.10; mesoZr‐Mn: 220,000; PDI: 1.05–1.10) possibly suggesting that these systems are close to living systems. © 2007 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 45: 5470–5479, 2007
Rapid additive‐free TEMPO‐mediated stable free radical polymerizations of styrene
Authors: Dollin Michael , Szkurhan Andrea R. , Georges Michael K. 
Published: October 2007

AbstractThe stable free radical polymerization (SFRP) of styrene, initiated with benzoyl peroxide in the presence of TEMPO, under bulk conditions, is demonstrated to proceed rapidly without the need for any rate enhancing additives such as camphorsulfonic acid, 2‐fluoro‐1‐methyl pyridinium p‐toluenesulfonate, or acetic anhydride. Monomer conversions as high as 70% can be achieved in 5 h or less while maintaining polydispersity indexes of 1.15. These results stand in stark contrast to earlier reactions that required 70 h to achieve similar conversions. This study demonstrates that the single largest factor governing the rates of polymerization is the molar concentration of excess TEMPO remaining in solution after initiation. A reduction in the TEMPO to BPO ratio is required when large amounts of BPO are used to target low molecular weight polystyrenes. However, when a lower molar amount of BPO is used to obtain high molecular weight polystyrenes, a higher TEMPO to BPO ratio is required. © 2007 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 45: 5487–5493, 2007
Synthesis and characterization of amphiphilic block copolymers with allyl side‐groups
Authors: Hu Xiuli , Chen Xuesi , Xie Zhigang , Liu Shi , Jing Xiabin 
Published: October 2007

AbstractThe synthesis of a new cyclic carbonate monomer containing an allyl group was reported and its biodegradable amphiphilic block copolymer, poly(ethylene glycol)‐block‐poly(L‐lactide‐co‐5‐methyl‐5‐allyloxycarbonyl‐propylene carbonate) [PEG‐b‐P(LA‐co‐MAC)] was synthesized by ring‐opening polymerization (ROP) of L‐lactide (LA) and 5‐methyl‐5‐allyloxycarbonyl‐1,3‐dioxan‐2‐one (MAC) in the presence of poly (ethylene glycol) as a macroinitiator, with diethyl zinc as a catalyst. 13C NMR and 1H NMR were used for microstructure identification of the copolymers. The copolymer could form micelles in aqueous solution. The core of the micelles is built of the hydrophobic P(LA‐co‐MAC) chains, whereas the shell is set up by the hydrophilic PEG blocks. The micelles exhibited a homogeneous spherical morphology and unimodal size distribution. By using the cyclic carbonate monomer containing allyl side‐groups, crosslinking of the PEG‐b‐P(LA‐co‐MAC) inner core was possible. The adhesion and spreading of ECV‐304 cells on the copolymer were better than that on PLA films. Therefore, this biodegradable amphiphilic block copolymer is expected to be used as a biomaterial for drug delivery and tissue engineering. © 2007 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 45: 5518–5528, 2007
The theory of nonrandom polycondensation for the description of sol–gel polymerization of alkoxisilanes
Authors: Tarasevich Konstantin V. , Kuchanov Semion I. 
Published: October 2007

AbstractThe earlier developed theory of nonrandom polycondensation (Kuchanov, et al. J Stat Phys 122, 875, 2006) is applied for the description of sol–gel polymerization of alkoxisilanes. The accuracy of simple approximate approaches used in literature to calculate critical conversion at the gel‐point is evaluated. The results of calculation of the characteristics of gel's polymer network governing its elastic properties are presented for the first time. © 2007 Wiley Periodicals, Inc. J Polym Sci Part B: Polym Phys 45: 3093–3116, 2007
Surface Chemical Analysis of Plasma‐Deposited Copolymer Films Prepared from Feed Gas Mixtures of Ethylene or Styrene with Allylamine
Authors: Swaraj Sufal , Oran Umut , Lippitz Andreas , Unger Wolfgang E. S. 
Published: October 2007

AbstractPlasma deposited ethylene/allylamine and styrene/allylamine copolymer films were prepared and analyzed using XPS, NEXAFS and ToF‐SIMS. The relative partial flow rate of the each monomer was used as the variable deposition parameter, while the other deposition parameters were kept constant at optimized values for the retention of functional groups. The effect of the variation in the relative partial flow rates of co‐monomers on various chemical aspects of the films like unsaturation, nitrogen retention and branching was investigated revealing several non‐linear correlations. This observation is taken as an indication for chemical copolymerization processes during film deposition. An attempt is made to compare these non‐linear correlations with approaches which have been developed for classic radical copolymerization processes. The aging behavior of these plasma copolymer films was also studied; the results indicated a stabilization against oxidation in comparison to the aging of allylamine plasma homopolymers.magnified image
Neuroproteomics in stem cell differentiation
Authors: Beyer Susanne , Mix Eilhard , Hoffrogge Raimund , Lünser Katja , Völker Uwe , Rolfs Arndt 
Published: October 2007

AbstractThe term “proteome” is used to describe the entire complement of proteins in a given organism or in a system at a given time. Proteome analysis in neuroscience, also called “neuroproteomics” or “neuromics” is in its initial stage, and shows a deficit of studies in the context of brain development. It is the main objective of this review to illustrate the potential of neuroproteomics as a tool to unravel the differentiation of neural stem or progenitor cells to terminally differentiated neurons. Experimental results regarding the rat striatal progenitor model cell line ST14A are presented to illustrate the large rearrangements of the proteome during the differentiation process of neural progenitor cells and their modification by neurotrophic factors like the glial cell line‐derived neurotrophic factor (GDNF). Thereby native stem cells and cells transfected with GDNF gene were investigated at the proliferative state and at seven time points up to 72 h after induction of differentiation. In addition, the immortalized human fetal midbrain stem cell line ReNcell VM was analyzed in order to detect stem cell differentiation associated changes of the protein profile. This review gives also an outlook on technical improvements and perspectives of application of neural stem cell proteomics.
Endogeneous peptide profiling of cerebrospinal fluid by MALDI‐TOF mass spectrometry: Optimization of magnetic bead‐based peptide capture and analysis of preanalytical variables
Authors: Jimenez Connie R. , Koel‐Simmelink Marleen , Pham Thang V. , van der Voort Laura , Teunissen Charlotte E. 
Published: October 2007

AbstractCerebrospinal fluid (CSF) perfuses the brain and spinal cord. CSF contains peptides and proteins important for brain physiology and potentially also relevant to brain pathology. High‐throughput endogeneous peptide profiling by MS is an emerging approach for disease diagnosis and biomarker discovery. A magnetic bead‐based method for off‐line serum peptide capture coupled to MALDI‐TOF‐MS has been introduced recently. In this study, we optimize the peptide capture method for profiling of CSF and investigate the effect of a number of preanalytical variables. The CSF profiles contain ∼100 reliably detected peptides at m/z 800–4000 with reproducible ion intensities (average 7% CV). The investigated preanalytical variables include: time at room temperature (RT) before storage, storage temperature, freeze‐thawing cycles, and blood contamination. The CSF peptidome (<20 kDa) is relatively stable and can withstand a few hours at RT and several freeze‐thaw cycles. Several peptides sensitive to storage at −20°C, including Cystatin C, were assigned based on mass or identified by MS/MS. Hemoglobin α and β chains were detected in blood contaminated samples, at levels invisible to the eye (0.01%). These peptides may be used for quality control in a MALDI‐TOF‐MS screening strategy to select high quality samples for in‐depth proteomics analysis in disease studies.